Angiotensin II type 2 receptor-mediated inhibition of norepinephrine release in isolated rat hearts

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 2, 2008, Pages 176-183

  Sasaoka, Tetsumasa ^a   Egi, Yasuhiro ^b   Tawa, Masashi ^a   Yamamoto, Ai ^a   Ohkita, Mamoru ^a   Takaoka, Masanori ^a   Maruyama, Tomoyuki ^b   Akira, Toshiaki ^b   Matsumura, Yasuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Angiotensin II; AT2 receptor; Bradykinin; Nitric oxide; Norepinephrine; Sympathetic neurotransmission

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ENZYME INHIBITOR; ICATIBANT; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; NITRIC OXIDE; PKSI 527; UNCLASSIFIED DRUG; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE; NORADRENALIN; OLIGOPEPTIDE; PHENYLALANINE; PYRIDINE DERIVATIVE; TRANEXAMIC ACID; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART NERVE; IMMUNOHISTOCHEMISTRY; ISOLATED HEART; MALE; NERVE STIMULATION; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN RELEASE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RAT; REPRODUCIBILITY; SYMPATHETIC NERVE; ADRENERGIC SYSTEM; ANIMAL; DRUG ANTAGONISM; HEART; IN VITRO STUDY; INNERVATION; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BRADYKININ; HEART; IMIDAZOLES; LOSARTAN; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NOREPINEPHRINE; OLIGOPEPTIDES; PHENYLALANINE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; SYMPATHETIC NERVOUS SYSTEM; TRANEXAMIC ACID; VASOCONSTRICTOR AGENTS;

EID: 56149114789     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31818127f8     Document Type: Article

References (32)

1. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptor. Pharmacol Rev. 2000; 52:415-472.
2. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182-1191.
3. Yayama K, Hori M, Hiyoshi H, et al. Up-regulation of angiotensin II type 2 receptor in rat thoracic aorta by pressure-overload. J Pharmacol Exp Ther. 2004;308:736-743.
4. 2 receptor comes of age. Hypertension. 2005;45: 840-844.
5. Inagami T. Molecular biology and signaling of angiotensin receptors: an overview. J Am Soc Nephrol. 1999;10:S2-S7.
6. Brasch H, Sieroslawski L, Dominiak P. Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension. 1993;22:699-704.
7. Suzuki Y, Matsumura Y, Egi Y, et al. Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on norepinephrine overflow and antidiuresis induced by stimulation of renal nerves in anesthetized dogs. J Pharmacol Exp Ther. 1992;263:956-963.
8. Wong PC, Bernard R, Timmermans PBMWM. Effects of blocking angiotensin II receptor subtype on rat sympathetic nerve function. Hypertension. 1992;19:663-667.
9. Akers WS, Cassis LA. Presynaptic modulation of evoked NE release contributes to sympathetic activation after pressure overload. Am J Physiol. 2004;286:H2152-H2158.
10. Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest. 2006;116:1063-1070.
11. Lameris TW, de Zeeuw S, Duncker DJ, et al. Exogenous angiotensin II does not facilitate norepinephrine release in the heart. Hypertension. 2002;40:491-497.
12. Nap A, Balt JC, Pfaffendorf M, et al. No involvement of the AT2-receptor in angiotensin II-enhanced sympathetic transmission in vitro. J Renin Angiotensin Aldosterone Syst. 2003;4:100-105
13. El Muayed M, Stegbauer J, Oberhauser V, et al. AT1 and AT2-receptor antagonists inhibit ang II-mediated facilitation of noradrenaline release in human atria. J Cardiovasc Pharmacol. 2004;43:318-324.
14. Yamamoto S, Matsumoto N, Fujita M, et al. Different contributions of endothelin-A and endothelin-B receptors in postischemic cardiac dysfunction and norepinephrine overflow in rat hearts. Circulation. 2005;111:302-309.
15. Konishi F, Okada Y, Takaoka M, et al. Role of endothelin ETB receptors in the renal hemodynamic and excretory responses to big endothelin-1. Eur J Pharmacol. 2002;451:177-184.
16. Shetty SJ, Delgrande D. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan. J Pharmacol Exp Ther. 2000;294:179-186.
17. Sato M, Engelman RM, Otani H, et al. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker. Circulation. 2000;102:III-346-III-351.
18. Hayashi K, Matsumura Y, Yoshida Y, et al. The role of endogenous angiotensin II in antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs. J Cardiovasc Pharmacol. 1991;17:807-813.
19. Grady EF, Sechi LA, Griffin CA, et al. Expression of AT2 receptors in the developing rat fetus. J Clin Invest. 1991;88:921-933.
20. Tsutsumi K, Stromberg C, Viswanathan M, et al. Angiotensin-II receptor subtypes in fetal tissue of the rat: Autoradiography, guanine nucleotide sensitivity, and association with phosphoinositide hydrolysis. Endocrinology. 1991;129:1075-1082.
21. 2) receptor protein in rat heart. Hypertension. 1998; 32:78-83.
22. Utsunomiya H, Nakamura M, Kakudo K, et al. Angiotensin II AT2 receptor localization in cardiovascular tissues by its antibody developed in AT 2 gene-deleted mice. Regul Pept. 2005;126:155-161.
23. 1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994;267:H844-H852.
24. Sechi LA, Griffin CA, Grady EF, et al. Characterization of angiotensin II receptor subtypes in rat heart. Circ Res. 1992;71:1482-1489.
25. Batenburg WW, Garrelds IM, Bernasconi CC, et al. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation. 2004;109:2296-2301.
26. Siragy HM, Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension. 2000;35: 1074-1077.
27. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodila-tion. J Clin Invest. 1999;104:925-935.
28. Yayama K, Hiyoshi H, Imazu D, et al. Angiotensin II stimulates endothelial NO synthase phosphorylation in thoracic aorta of mice with abdominal aortic banding via type 2 receptor. Hypertension. 2006;48: 958-964.
29. Egi Y, Matsumura Y, Murata S, et al. The effects of NG-nitro-L-arginine, a nitric oxide synthase inhibitor, on norepinephrine overflow and antidiuresis induced by stimulation of renal nerves in anesthetized dogs. J Pharmacol Exp Ther. 1994;269:529-535.
30. Schwarz P, Diem R, Dun NJ, et al. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res. 1995;77:841-848.
31. Liu Y-H, Yang X-P, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest. 1997;99:1926-1935.
32. Abadir PM, Periasamy A, Carey RM, et al. Angiotensin II type 2 receptors bradykinin B2 receptor functional heterodimerization. Hypertension. 2006;48:316-322.